Fig. 2

EC2319 treatment effects in rats during the chronic phase of fDTH-EAE. a Low- and high-power magnification photomicrographs of double immunofluorescence staining for FR-β and CD68 in fDTH-EAE rat brain cryosections. b High-power magnification photomicrographs of FR-β and iNOS or MRC-1 double staining in fDTH-EAE cryosections. Scale bars, 50 μm (high power) and 2 mm (low power). c Quantification of FR-β and CD68 positivity, lymphocyte count densities, lesion areas, iNOS/MRC-1 ratios, and demyelination areas on day 90 with representative LFB staining. d Representative in vitro autoradiographs of ⁶⁸Ga-FOL total binding and folate glucosamine-blocked binding with corresponding H&E-stained sections. Scale bar, 2 mm. e Quantification of in vitro ⁶⁸Ga-FOL total and folate glucosamine-blocked binding. f Representative ex vivo autoradiographs and in vivo PET/CT images of ⁶⁸Ga-FOL from fDTH-EAE rats treated with EC2319 or saline. g Quantification of PET data at day 90. Error bars denote SDs. White arrows indicate lesion site